OncoDNA, SOLTI Agreement to Provide Molecular Profile Analysis
News Oct 27, 2016
Belgium-based OncoDNA SA, The Cancer Theranostic Company, which supplies the only comprehensive solution from cancer profiling (OncoDEEP&TRACE), combining solid and liquid biopsies analysis to help oncologists with drug treatment options and efficacy monitoring, has signed a partnership agreement, through its Spanish distributor BioSequence, with SOLTI, a non-profit organization dedicated to clinical research in breast cancer with a broad network of leading hospital centers in Spain, Portugal, France and Italy to supply tumor molecular profiling analysis for SOLTI’s AGATA breast cancer screening program.
AGATA, the pilot trial of a genomic screening program pioneered in Spain, aims to refer breast cancer patients to clinical trials based on their molecular profile. With this partnership, SOLTI takes advantage of OncoDNA’s solid experience in data processing to streamline and customize patient data collection.
“This collaboration is a great opportunity to exchange knowledge and know-how between OncoDNA and SOLTI, both organizations focused on improving cancer patient care. We are excited to work together to enhance the outcomes we provide through the AGATA program to better direct patients to clinical trials according to their tumor profile,” said Dr. Eva Ciruelos, President of SOLTI.
Jean-François Laes, CTO of OncoDNA, said: “We are happy that the first OncoKDM collaboration we can announce publicly is with this renowned SOLTI breast cancer group. Our goal when we developed OncoKDM was to propose access to our database and share our expertise. This project gathering molecular data from different technology and geographical origins illustrates the advantage of a centralized, harmonized and expert oncology system to improve cancer patient care.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.